
|Videos|July 24, 2014
Observation Versus Treatment in Men with Prostate Cancer
Author(s)Peter Yu, MD
Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men’s treatment decisions after seeing a rise in their PSA levels. <
Advertisement
Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men’s treatment decisions after seeing a rise in their PSA levels.
Clinical Pearls:
- One of the studies presented at the 2014 ASCO Annual Meeting reviewed data of men who decided to wait or pursue treatment.
- Results of this study showed there was no difference in survival regardless of their decision.
- Men and doctors can now better discuss remaining on observation or starting treatment.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
2
Cost-Effectiveness of Perioperative Pembro in Head and Neck Cancer Hinges on PD-L1 Expression
3
FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs
4
Dr Lonial on Using MRD Negativity to Guide Maintenance Discontinuation in Myeloma
5







































